VNDA vs VTRS: fair value comparison
Vanda Pharmaceuticals Inc. and Viatris Inc. · Updated 2026-10-19
VNDA is still awaiting a full valuation verdict under our six-validated-windows standard. VTRS is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, VNDA currently ranks higher by quality score.
| VNDA | VTRS | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $4.03 | $17.64 |
| 12-month range | $4.03–$9.56 | $10.11–$18.66 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #139 of 301 Healthcare | #140 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: VNDA fair value analysis · VTRS fair value analysis